https://www.nature.com/articles/s41598-017-10407-w
An attempt to wake up the medical community to accept research done in the last 100 years proving that electromagnetic energy can replace brutal chemotherapy. Photo taken by a professional photographer, of his own daughter being treated for Neuroblastoma. The power of the image encouraged Andy to share it with others in order to highlight the 'real' face of childhood cancer. She died. The average cost for such treatment is in the order of 500k+.
Wednesday, November 15, 2017
Low Frequency Magnetic Fields Induce Autophagy-associated Cell Death in Lung Cancer through miR-486-mediated Inhibition of Akt/mTOR Signaling Pathway
Low frequency magnetic fields (LF-MFs) can affect cell proliferation in a cell-type and intensity-dependent way. Previous study has reported the anti-tumor effect of LF-MFs in lung cancers. Our previous study also optimized the intensity and duration of LF-MFs to effectively inhibit the proliferation of lung cancer cells. However, the anti-tumor mechanism of LF-MFs remains unclear, which limit the clinical application of LF-MFs in anti-tumor therapy. Here, in a well-established Lewis Lung Cancer (LLC) mouse model, we found that LF-MFs inhibit tumor growth and induce an autophagic cell death in lung cancer. We also found that LF-MFs could up-regulate the expression level of miR-486, which was involved in LF-MFs activated cell autophagy. Furthermore, we found B-cell adaptor for phosphatidylinositol 3-kinase (BCAP) is a direct target of miR-486. miR-486 inhibit AKT/mTOR signaling through inhibiting expression of BCAP. Moreover, a decreased expression of miR-486 and an increased expression of BCAP were found in tumor tissues of lung cancer patients. Taken together, this study proved that LF-MFs can inhibit lung cancers through miR-486 induced autophagic cell death, which suggest a clinical application of LF-MFs in cancer treatment.
https://www.nature.com/articles/s41598-017-10407-w
https://www.nature.com/articles/s41598-017-10407-w
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment